Glenmark Pharmaceuticals Shifts Focus to Directly Market RYALTRIS® in the U.S. Expanding Innovative Portfolio

Glenmark Pharmaceuticals Makes Strategic Move

Glenmark Pharmaceuticals Inc., USA, has made an important announcement regarding the commercialization and distribution of its nasal spray product, RYALTRIS®. Effective from April 1, 2026, Glenmark will oversee all aspects of marketing and distribution of RYALTRIS® directly within the United States. This strategic decision symbolizes a major step in the company’s efforts to expand its presence in the U.S. market and demonstrates a commitment to a sustainable approach that enhances its commercial capabilities.

RYALTRIS®, officially launched in the U.S. in 2022, addresses symptoms associated with Seasonal Allergic Rhinitis (SAR) for adults and pediatric patients aged 12 and older. It is a fixed-dose nasal spray that combines two well-known medications: olopatadine hydrochloride (an antihistamine) and mometasone furoate (a corticosteroid). Each spray delivers 665 mcg of olopatadine and 25 mcg of mometasone, providing a comprehensive treatment option for a condition that affects millions of individuals across the U.S.

With the growing prevalence of Seasonal Allergic Rhinitis, effective symptom control is vital for patients. RYALTRIS® offers a convenient solution by integrating two established therapies into one formulation, simplifying treatment for both patients and healthcare providers. The direct management of RYALTRIS®'s commercialization allows Glenmark to align more closely with medical professionals and respond swiftly to market needs, ultimately enhancing the patient experience.

Marc Kikuchi, President and Business Head for North America at Glenmark, expressed, “Our decision to lead the commercialization of RYALTRIS® in the United States reflects our ongoing growth strategy. It enables us to engage more effectively with healthcare providers and support patients throughout the nation. Furthermore, this move is integral to our broader commitment to strengthen our innovative presence in the U.S. market.”

The product has already gained approval in significant markets such as the European Union, United Kingdom, Australia, South Korea, Russia, and China. In the fiscal year 2026, RYALTRIS® was also successfully launched in 11 additional countries, bringing its availability to a total of 55 worldwide.

Glenmark Pharmaceuticals, listed as BSE 532296 and NSE GLENMARK, is renowned for its focus on research and innovation, striving to provide access to high-quality medicines globally. Their operations include 11 state-of-the-art manufacturing facilities and six research and development centers across four continents. They have established a strong market footprint in over 80 countries, emphasizing their commitment to respiratory, dermatology, and oncology treatments.

With their sights set firmly on the future, Glenmark is poised to leverage this significant shift by directly controlling the commercialization of RYALTRIS®, enhancing operational efficiency while strengthening its market position. The company aims to continually evolve alongside patient needs and therapeutic innovations, maintaining its commitment to deliver exceptional healthcare solutions worldwide.

For more information about RYALTRIS® and how to access it, visit the official Glenmark website: www.ryaltris.com.